OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
about
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.Bromodomain inhibitors and cancer therapy: From structures to applications.Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies.Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine GliomaMitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.Cancer: Keeping it real to kill glioblastoma.Antagonistic effects of nitric oxide in a glioblastoma photodynamic therapy model:mitigation by BET bromodomain inhibitor JQ1.Targeting of epigenetic regulators in neuroblastoma.The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphomaReplication-dependent histone isoforms: a new source of complexity in chromatin structure and functionCombined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity
P2860
Q37702577-4BB944B1-AE85-44A5-8B82-FD4B17ABA8C0Q37705651-34AC44DE-5761-496A-8815-FD7FFD601FA5Q38677019-61A2D957-99AA-479B-9142-A19FE6B0B07CQ38771703-008A51C9-63C6-40C3-AB85-4D95787938B7Q39024306-75EBB1EA-8E7D-499D-A1D3-5D404A802967Q39027056-A50670D3-9320-4F56-878F-A1DEAD10EE3DQ39069889-97FBF1E8-000E-4235-A3F8-82F5FD87DDCBQ39154575-C4EE3370-30DF-40F6-AD93-816315AF0AAFQ41043950-FCD12885-01C8-4631-84BC-B2AF95489A77Q41879630-D9C7DF9C-B336-4421-AFAC-BA82FE6CC6DBQ48210831-96F9A959-9B79-44C3-A58A-53784D1ADBA7Q50027143-5C8C6649-FE11-4608-AF03-71BEF8D9DEA6Q52560224-A258A4F7-3FC7-4166-B2DC-0C567335A042Q52680700-14DFF1AD-0F57-4D26-8D0B-DE56BBDB3655Q54957650-1B41700A-4179-42A8-A1AF-6F4FD95D00BDQ55457087-9CD73BA8-3AB2-4905-B68C-F658D8A1D993Q57270689-5C29DEB5-952B-481B-A360-6FBE21B054C2Q58700196-EEC84445-185A-4932-AE0A-A9B9F4B15295Q58746764-BB723284-90F2-4EB3-AC22-456ECCDA29E6
P2860
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
OTX015 (MK-8628), a novel BET ...... rapies in glioblastoma models.
@en
type
label
OTX015 (MK-8628), a novel BET ...... rapies in glioblastoma models.
@en
prefLabel
OTX015 (MK-8628), a novel BET ...... rapies in glioblastoma models.
@en
P2093
P2860
P50
P356
P1476
OTX015 (MK-8628), a novel BET ...... rapies in glioblastoma models.
@en
P2093
Caroline Berenguer-Daizé
Elodie Odore
Esteban Cvitkovic
François Lokiec
Keyvan Rezai
Lucile Astorgues-Xerri
Maria E Riveiro
Mohamed Bekradda
Mylène Cayol
P2860
P304
P356
10.1002/IJC.30256
P577
2016-07-07T00:00:00Z